These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effects of the administration of B663 [G 30 320, Lamprene, clofazimine (Geigy)] on three groups of lepromatous and borderline of leprosy. Rodriguez JN; Abalos RM; Reich CV; Tolentino JG Int J Lepr Other Mycobact Dis; 1974; 42(3):276-88. PubMed ID: 4617715 [No Abstract] [Full Text] [Related]
23. Erythema dyschromicum perstans in phototype II women: three unusual clinical cases studied with electron microscopy. Persechino S; Caperchi C; Cortesi G; Persechino F; Raffa S; Pulcini F; Tammaro A; Torrisi MR Eur J Dermatol; 2011; 21(2):261-2. PubMed ID: 21382781 [No Abstract] [Full Text] [Related]
24. Limitations of clofazimine in the treatment of lepra reactions. Mishra B; Girdhar BK Indian J Lepr; 1986; 58(1):73-8. PubMed ID: 3746000 [TBL] [Abstract][Full Text] [Related]
25. Erythema Dyschromicum Perstans Response to Isotretinoin. Wang F; Zhao YK; Wang Z; Liu JH; Luo DQ JAMA Dermatol; 2016 Jul; 152(7):841-2. PubMed ID: 26933923 [No Abstract] [Full Text] [Related]
27. Clofazimine (Lamprene, B663) in the treatment of lepromatous leprosy in the United Kingdom. A 12 year review of 31 cases, 1966-1978. Browne SG; Harman DJ; Waudby H; McDougall AC Int J Lepr Other Mycobact Dis; 1981 Jun; 49(2):167-76. PubMed ID: 7196886 [TBL] [Abstract][Full Text] [Related]
28. The antileprotic action of clofazimine (B663, G30, 320, Lamprene). Azulay RD; da Silva NC; Zeo A; Portela AB; Franca JC; Peluso LL Int J Lepr Other Mycobact Dis; 1974; 42(1):13-8. PubMed ID: 4607163 [No Abstract] [Full Text] [Related]
29. Role of rifampin and clofazimine ointments in the treatment of leprosy. Venkateswarlu B; Venkataramana D; Rao AV; Prabhakar MC; Reddy BM Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):269-70. PubMed ID: 1522368 [TBL] [Abstract][Full Text] [Related]
30. Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. Kroon MW; Wind BS; Meesters AA; Wolkerstorfer A; van der Veen JP; Bos JD; Van der Wal AC; Beek JF J Dermatolog Treat; 2012 Oct; 23(5):339-44. PubMed ID: 21756152 [TBL] [Abstract][Full Text] [Related]